ROXYBOND Drug Patent Profile
✉ Email this page to a colleague
When do Roxybond patents expire, and when can generic versions of Roxybond launch?
Roxybond is a drug marketed by Protega Pharms and is included in one NDA. There are two patents protecting this drug.
This drug has twenty-three patent family members in ten countries.
The generic ingredient in ROXYBOND is oxycodone hydrochloride. There are nineteen drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the oxycodone hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Roxybond
A generic version of ROXYBOND was approved as oxycodone hydrochloride by SPECGX LLC on June 30th, 2004.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ROXYBOND?
- What are the global sales for ROXYBOND?
- What is Average Wholesale Price for ROXYBOND?
Summary for ROXYBOND
| International Patents: | 23 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 3 |
| Raw Ingredient (Bulk) Api Vendors: | 28 |
| Patent Applications: | 2,337 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ROXYBOND |
| What excipients (inactive ingredients) are in ROXYBOND? | ROXYBOND excipients list |
| DailyMed Link: | ROXYBOND at DailyMed |
Pharmacology for ROXYBOND
| Drug Class | Opioid Agonist |
| Mechanism of Action | Full Opioid Agonists |
US Patents and Regulatory Information for ROXYBOND
ROXYBOND is protected by two US patents.
Patents protecting ROXYBOND
Pharmaceutical compositions configured to deter dosage form splitting
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Abuse resistant drugs, method of use and method of making
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Protega Pharms | ROXYBOND | oxycodone hydrochloride | TABLET;ORAL | 209777-001 | Apr 20, 2017 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Protega Pharms | ROXYBOND | oxycodone hydrochloride | TABLET;ORAL | 209777-003 | Apr 20, 2017 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Protega Pharms | ROXYBOND | oxycodone hydrochloride | TABLET;ORAL | 209777-004 | Sep 5, 2024 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ROXYBOND
See the table below for patents covering ROXYBOND around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Mexico | 2010001812 | FARMACOS RESISTENTES AL ABUSO, METODO DE USO Y METODO DE FABRICACION. (ABUSE RESISTANT DRUGS, METHOD OF USE AND METHOD OF MAKING.) | ⤷ Sign Up |
| Japan | 6608319 | ⤷ Sign Up | |
| Japan | 5965583 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ROXYBOND
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1685839 | 92292 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
